“Low-grade positivity” of HPV viral load after atypical squamous cells of undetermined significance (ASC-US) cytology identifies women at low-risk for cervical intraepithelial neoplasia grade 2 and 3

The correlation between high-risk HPV-DNA viral load, expressed as relative light units (RLU) values obtained from the Hybrid Capture 2 (HC2) test, and the prevalence of CIN2/CIN3 was investigated and statistically analyzed in 614 ASC-US consecutive cases. Cases were categorized into three groups according to RLU values: "low-grade positivity", "intermediate positivity" and "high-grade positivity", and the prevalence of CIN2/CIN3 was evaluated in the single groups and compared among them. CIN/CIN3 rates demonstrated a significant (p < 0.001) increase with a direct correlation with increasing RLU values: 4.6% (RLU from 1.0 to 10.0), 9.1% (RLU from 11.0 to 100.0) and 32.2% (RLU > 100.0) respectively. The prevalence of CIN2/CIN3 between the group with RLU < 10.0 (4.6%) and the group with RLU > 10 (24.2%) showed statistical significance (p = 0.0002). Increasing hrHPV viral load significantly correlates with increasing prevalence of CIN2/CIN3 in ASC-US cases.

ASC-US; HPV; HPV-DNA; viral load; HC2; Cervical Intraepithelial Neoplasia; CIN

[1] Waggoner S.E.: “Cervical cancer”. Lancet, 2003, 361, 2217.

[2] Mathew A., George P.S.: “Trends in incidence and mortality ratesod squamous cell carcinoma and adenocacrcinoma of cervix-worldwide”. Asian Pac. J. Cancer Prev., 2009, 10, 645.

[3] Solomon D., Schiffman M., Tarone R., ALTS Study group: “Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial”. J. Natl. Cancer Inst., 2001, 93, 293.

[4] Wang J., Wu M., Zhang S., Li C., Zhang W.: “Prevalence of cervical intraepithelial neoplasia in patients with atypical squamous cells of undetermined significance from cervical pap smears in Beijing”. Eur. J. Gynaecol. Oncol., 2011, 32, 411.

[5] Poomtavorn Y., Suwannarurk K., Thaweekul Y., Maireang K.: “Risk factors for high-grade cervical intraepithelial neoplasia in patients with atypical squamous cells of undetermined significance (ASC-US) papanicolaou smears”. Asian Pac. J. Cancer Prev., 2011, 12, 235.

[6] Runowicz C.D.: “Molecular screening for cervical cancer - time to give up Pap test?”. N. Engl. J. Med., 2007, 357, 1650.

[7] Wright T.C. Jr., Cox J.T., Massad L.S., Twiggs L.B., Wilkinson E.J. 2006 ASCCP-Sponsored Consensus Conference: “2006 Consensus guidelines for the management of women with abnormal cervical cancer screening”. Am. J. Obstet. Gynecol., 2007, 197, 346.

[8] Arbyn M., Sasieni P., Meijer C.J., Clavel C., Koliopoulos G., Dillner J. Chapter 9: “Clinical applications of HPV testing: a summary of meta-analyses”. Vaccine, 2006, 24 (suppl. 3), S3/78.

[9] The ASCUS-Low SIL Triage Study (ALTS) Group: “Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance”. Am. J. Obstet Gynecol., 2003, 188, 1383.

[10] Xu Y., Dotto J., Hui Y., Lawton K., Schofield K., Hui P.: “High grade cervical intraepithelial neoplasia and viral load of high-risk human papillomavirus: significant correlations in patients of 22 years old or younger”. Int. J. Clin. Exp. Pathol. 2009, 2, 169.

[11] Flores R., Papenfuss M., Klimecki W.T., Giuliano A.R.: “Crosssectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia”. Int. J. Cancer, 2006, 118, 1187.

[12] Tsai H.T., Wu C.H., Lai H.L., Li R.N., Tung Y.C., Chuang H.Y. et al.: “Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk”. Cancer Epidemiol Biomarkers Prev., 2005 (11 Pt 1), 2544.

[13] Cuzick J., Beverley E., Ho L., Terry G., Sapper H., Mielzynska I. et al.: “HPV testing in primary screening of older women”. Br. J. Cancer, 1999, 81, 554.

[14] Runowicz C.D.: “Molecular screening for cervical cancer - time to give up Pap test?”. N. Engl. J. Med., 2007, 357, 1650.

[15] Lorincz A.T., Castle P.E., Sherman M.E., Scott D.R., Glass A.G., Wacholder S. et al.: “Viral load of human papillomavirus and risk of CIN3 or cervical cancer”. Lancet, 2002, 360, 228.

[16] Sherman M.E., Wang S.S., Wheeler C.M., Rich L., Gravitt P.E., Tarone R., Schiffman M.: “Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions”. Cancer Epidemiol. Biomarkers Prev., 2003, 12, 1038.

[17] Dane C., Batmaz G., Dane B., Cetin A.: “Screening properties of human papillomavirus testing for predicting cervical intraepithelial neoplasia in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion tests: a prospective study”. Ann. Diagn. Pathol., 2009, 13, 73.

[18] Ordi J., Alonso I., Torné A., Esteve R., Sierra E., Campo E., Puig-Tintoré L.M.: “Human papillomavirus load in Hybrid Capture II assay: does increasing the cutoff improve the test?”. Gynecol. Oncol., 2005, 99, 313.

[19] Sargent A., Bailey A., Turner A., Almonte M., Gilham C., Baysson H. et al.: “Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial”. J. Clin. Microbiol., 2010, 48, 554.

[20] Castle P.E., Lorincz A.T., Mielzynska-Lohnas J., Scott D.R., Glass A.G., Sherman M.E. et al.: “Results of human papillomavirus DNA testing with the Hybrid Capture 2 assay are reproducible”. J Clin Microbiol., 2002, 40, 1088.

[21] De Cremoux P., Coste J., Sastre-Garau X., Thioux M., Bouillac C., Labbe S. et al.: “Efficiency of the Hybrid Capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology”. Am J Clin Pathol., 2003, 120, 492.

[22] Jarboe E.A., Venkat P., Hirsch M.S., Cibas E.S., Crum C.P., Garner E.I.: “A weakly positive human papillomavirus Hybrid Capture II result correlates with a significantly lower risk of cervical intraepithelial neoplasia 2,3 after atypical squamous cells of undetermined significance cytology”. J. Low Genit. Tract. Dis., 2010, 14, 174.

[23] Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R. et al.: “The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice”. J. Natl. Cancer Inst., 2005, 97, 1072.

[24] Yoshida T., Sano T., Kanuma T., Inoue H., Itoh T., Yazaki C. et al.: “Usefulness of CINtec PLUS p16/Ki-67 Double-Staining in Cytological Screening of Cervical Cancer”. Acta Cytol., 2011, 55, 413.